MaxCyte, Inc.

NasdaqGS MXCT

MaxCyte, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -20.21

MaxCyte, Inc. Interest Coverage Ratio is -20.21 for the Trailing 12 Months (TTM) ending September 30, 2024. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

MaxCyte, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -37.19, a -216.20% change year over year.
MaxCyte, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -11.76, a 51.60% change year over year.
MaxCyte, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -24.30.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqGS: MXCT

MaxCyte, Inc.

CEO	Mr. Maher Masoud
IPO Date	July 30, 2021
Location	United States
Headquarters	9713 Key West Avenue
Employees	143
Sector	Healthcare
Industries Biotechnology 3D Printing

Description

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Key trends

Past 5 years